11 results about "Jnk inhibitor" patented technology

Disclosed herein are methods of increasing sensitivity of a cancer cell to alternating electric fields comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of treating a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using an alternating electric field for a period of time, the alternating electric field having a frequency and field strength in combination with either an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength; and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor.

Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1 / 2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.

This document describes methods for increasing the sensitivity of a cancer cell to alternating electric fields, comprising exposing the cancer cell to an alternating electric field for a specified period of time, said alternating electric field having a specified frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, a JNK inhibitor, an RPS6 inhibitor, or an ERK inhibitor. It also describes methods for increasing the efficacy of the treatment, comprising applying an alternating electric field to a target site on the subject for a specified period of time, said alternating electric field having a specified frequency and field strength, wherein the target site comprises one or more cancer cells, and administering to the subject a therapeutically effective amount of one or more inhibitors of IGF1R, JNK, RPS6, and / or ERK.Methods for treating a subject with cancer are described, comprising applying an alternating electric field to a target site of the subject for a period of time, said alternating electric field having a determined frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more inhibitors of IGF1R, JNK, RPS6, and / or ERK to the subject. Methods for reducing the viability of cancer cells using an alternating electric field for a period of time, said alternating electric field having a determined frequency and field strength, in combination with an inhibitor of IGF1R, JNK, RPS6, and / or ERK, are described.Methods for increasing apoptosis of a cancer cell are described comprising exposing the cancer cell to an alternating electric field for a period of time, said alternating electric field having a determined frequency and field intensity; and exposing the cancer cell to an inhibitor of IGFR1, JNK, RPS6 or ERK.

The invention belongs to the technical field of bioengineering, and particularly provides application of a JNK inhibitor in preparation of drugs for preventing and / or relieving and / or treating pulmonary tuberculosis aiming at the problem that whether the existing JNK inhibitor SP600125 can inhibit BNIP3-mediated mitochondrial autophagy and further exert the ROS bactericidal effect is unknown. And the JNK inhibitor is an SP600125 JNK inhibitor. The JNK inhibitor is used for inhibiting mitochondrial autophagy in the BCG infected macrophages. The JNK inhibitor reduces the up-regulation of BNIP3 and LC3B caused by BCG infection. It is found through the application that when the concentration of the JNK inhibitor reaches 15 umol / L, remarkable cytotoxicity begins to appear, and compared with a control group, the cell survival rate is remarkably decreased. The SP600125 can be used for inhibiting mitochondrial autophagy and down-regulating the expression of BNIP3 and LC3B. Inhibition of JNK expression can inhibit survival of Mtb in RAW264.7 macrophages, and a new thought and direction are provided for treatment of tuberculosis.

Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1 / 2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.

The application discloses a medicine composition and pharmaceutical use of a combination of a JNK inhibitor and a PARG inhibitor. The application discloses for the first time that the JNK inhibitor (such as BIRB 796) and the PARG inhibitor (such as PDD00017273) can improve the synergistic effect of treating gastric cancer, the two inhibitors have a synergistic effect when used in combination, have a synergistic effect, realize a significant improvement of an anti-tumor effect, and do not increase the toxicity to various organs by the combination, but rather reduce the dosage of various drugs, thereby reducing the side effects, and have a significant significance for the application of the combination of the PARG inhibitor and the JNK inhibitor to the treatment of gastric cancer.

The invention discloses a pharmaceutical composition of JNK inhibitor and PARG inhibitor combined medication and pharmaceutical application. The invention discloses for the first time that the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273) have the synergistic effect on improving the gastric cancer treatment effect, the two inhibitors have the synergistic effect when being combined for use, the anti-tumor effect is remarkably improved, toxicity to each organ is not increased through combined use, and the effect of treating the gastric cancer can be obviously improved through combined use of the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273). On the contrary, the dosage of various medicines is reduced, so that the toxic and side effects are reduced, and the obvious significance is realized on the gastric cancer resisting application of PARG inhibitor and JNK inhibitor combined medication.

Disclosed are compounds, compositions, and methods for treating and / or preventing neurodegenerative diseases and disorders. Particularly disclosed are compounds, compositions, and methods for treating and / or preventing neurodegenerative diseases and disorders such as spinocerebellar ataxia type 1 (SCA1) by administering a JNK inhibitor.

Disclosed herein are methods of increasing sensitivity of a cancer cell to alternating electric fields comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of treating a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using an alternating electric field for a period of time, the alternating electric field having a frequency and field strength in combination with either an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength; and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor.

The present invention provides a compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, N-oxide or a pharmaceutically acceptable salt thereof, which can be used as a JNK inhibitor. Also provided are a method for preparing the compound represented by formula (I), a pharmaceutical composition comprising the compound represented by formula (I), and the use of the compound represented by formula (I) for preparing a medicament for treating a disease that can be treated by inhibiting JNK activity.